Incyte Jakafi outlook still positive after label revisions, says Oppenheimer

After the FDA revised the label of Incyte's Jakafi drug by adding new recommended dosing for patients with low platelet counts and a warning about PML, Oppenheimer views the dosing change as positive and doesn't think the warning will impact adoption. The firm reiterates an Outperform rating on the stock.

View Comments (0)